Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?

Several GLP-1 receptor agonists are currently available for treatment of type 2 diabetic patients. Based on their pharmacokinetic/pharmacodynamic profile, these drugs are classified as short-acting GLP-1 receptor agonists (exenatide and lixisenatide) or long-acting GLP-1 receptor agonists (exenatide...

Descripción completa

Detalles Bibliográficos
Autores principales: Miñambres, Inka, Pérez, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241936/
https://www.ncbi.nlm.nih.gov/pubmed/28115994
http://dx.doi.org/10.1186/s13098-017-0204-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241936/
https://www.ncbi.nlm.nih.gov/pubmed/28115994
http://dx.doi.org/10.1186/s13098-017-0204-6

Ejemplares similares